Scarica l'app Stockscreener
161.46
1.60%
-2.62
Dopo l'orario di chiusura:
161.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat
Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat
AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView
AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView
Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com
DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory - Bitget
Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset - Sahm
Citigroup Inc. Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,726,990.64 in Stock - MarketBeat
Mark Coleman Sells 25,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome (NASDAQ: AXSM) CEO awarded 54,623 RSUs vesting by 2030 - Stock Titan
[Form 4] Axsome Therapeutics, Inc. Insider Trading Activity - Stock Titan
Axsome Therapeutics (AXSM) director completes 25,000-share 10b5-1 sale - Stock Titan
Axsome Therapeutics Executives Sell Shares Worth Over $9.7 Million - TradingView
Axsome Opens CLARITY Trial As Solriamfetol Targets Underserved MDD Patients - Yahoo Finance
Axsome’s $7.75 Million Investor Settlement Gets Court Sendoff - Bloomberg Law News
Q1 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
AXSM (NASDAQ: AXSM) affiliate to sell 35,378 Class A shares via cashless exercise - Stock Titan
Smart Money Is Betting Big In AXSM OptionsAxsome Therapeutics (NASDAQ:AXSM) - Benzinga
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Vanguard Group Inc. - MarketBeat
Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. - MarketBeat
Axsome Therapeutics (AXSM) director exercises 6,250 options and holds shares - Stock Titan
Axsome Therapeutics at Oppenheimer Conference: Strategic Focus on Growth By Investing.com - Investing.com Australia
Axsome Therapeutics at Oppenheimer Conference: Strategic Focus on Growth - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Wolfe Research initiates Axsome stock with outperform rating By Investing.com - Investing.com Canada
Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Wolfe Research - MarketBeat
Axsome (AXSM) Q4 2025 Earnings Call Transcript - AOL.com
Dana Investment Advisors Inc. Grows Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Patent Deal Extends Sunosi Horizon And Clarifies Revenue Outlook - Sahm
Guggenheim Raises Axsome Therapeutics (AXSM) Price Target to $22 - GuruFocus
UBS raises Axsome Therapeutics stock price target on sales force expansion - Investing.com Nigeria
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - Finviz
Axsome Therapeutics (AXSM) Receives Updated Analyst Rating and T - GuruFocus
UBS Adjusts Axsome Therapeutics Price Target to $251 From $248, Maintains Buy Rating - marketscreener.com
Wolfe Research initiates Axsome stock with outperform rating - Investing.com
Axsome Therapeutics Q4 Revenue Surge Tests Bulls’ Profitability Narrative - simplywall.st
This Gentherm Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research Initiates Coverage of Axsome Therapeutics (AXSM) with Outperform Recommendation - Nasdaq
RBC Raises Price Target on Axsome Therapeutics to $222 From $219, Keeps Outperform Rating - marketscreener.com
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms - The Manila Times
Axsome Therapeutics initiates clarity phase 3 trial of solriamfetol in adults with major depressive disorder - marketscreener.com
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of - GlobeNewswire
Cowen Maintains Buy on Axsome Therapeutics (AXSM) Feb 2026 - Meyka
Axsome Therapeutics Signals Strong Growth in Earnings Call - The Globe and Mail
Decoding Axsome Therapeutics Inc (AXSM): A Strategic SWOT Insigh - GuruFocus
TD Cowen raises Axsome stock price target to $215 on Auvelity growth By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc earnings beat by $0.17, revenue topped estimates - Investing.com UK
Axsome (AXSM) director boosts stake by exercising 12,485 options - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
Axsome Therapeutics Inc (AXSM) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Truist reiterates Buy on Axsome stock ahead of April regulatory decision - Investing.com Canada
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):